Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Avapritinib

VOYAGER

Blueprint Medicines · Phase 3 · Completed · Enrollment 476

NCT03465722

ArmPopulationDoseEstimandComparatorEfficacy
Avapritinib 300 mg3L or later GIST (n = 240)300 mgITTregorafenib 160 mgmedian progression-free survival: 4.2 months, primary analysisprogression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055objective response rate: 17.1%, primary analysis
Regorafenib 160 mg3L or later GIST (n = 236)160 mgITTn/rmedian progression-free survival: 5.6 months, primary analysisobjective response rate: 7.2%, primary analysis